EHA 2025: Zanubrutinib Effective as First-Line CLL/SLL Therapy Regardless of del(17p)

At EHA 2025, five-year follow-up data from the SEQUOIA study were presented, demonstrating sustained efficacy of zanubrutinib in treatment-naïve, higher-risk patients with CLL/SLL, regardless of del(17p) status. Progression-free survival (PFS) benefits remained consistent over time.
In this MEDtalk, Professor Paolo Ghia, Università Vita-Salute San Raffaele, Milan, Italy, shares his clinical insights on the long-term data and its implications for frontline treatment strategies of patients with or without del(17p) status.